$1.98 Billion is the total value of Rock Springs Capital Management LP's 149 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDT | New | MEDTRONIC PLC | $35,500,000 | – | 400,000 | +100.0% | 1.79% | – |
| MRSN | New | MERSANA THERAPEUTICS INC | $21,345,000 | – | 1,527,893 | +100.0% | 1.08% | – |
| TMO | New | THERMO FISHER SCIENTIFIC INC | $19,192,000 | – | 110,000 | +100.0% | 0.97% | – |
| MOH | New | MOLINA HEALTHCARE INC | $18,229,000 | – | 263,500 | +100.0% | 0.92% | – |
| BCR | New | BARD C R INC | $18,176,000 | – | 57,500 | +100.0% | 0.92% | – |
| BAX | New | BAXTER INTL INC | $13,924,000 | – | 230,000 | +100.0% | 0.70% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $8,375,000 | – | 105,000 | +100.0% | 0.42% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INCcall | $7,864,000 | – | 140,000 | +100.0% | 0.40% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $7,847,000 | – | 139,700 | +100.0% | 0.40% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $7,675,000 | – | 307,000 | +100.0% | 0.39% | – |
| LXRX | New | LEXICON PHARMACEUTICALS INCcall | $6,473,000 | – | 393,500 | +100.0% | 0.33% | – |
| AXGN | New | AXOGEN INC | $6,281,000 | – | 375,000 | +100.0% | 0.32% | – |
| New | NABRIVA THERAPEUTICS PLC | $5,502,000 | – | 525,000 | +100.0% | 0.28% | – | |
| GTHX | New | G1 THERAPEUTICS INC | $5,445,000 | – | 312,188 | +100.0% | 0.28% | – |
| New | MEDICINES COnote 2.750% 7/1 | $5,256,000 | – | 5,000,000 | +100.0% | 0.26% | – | |
| SGEN | New | SEATTLE GENETICS INC | $5,174,000 | – | 100,000 | +100.0% | 0.26% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $4,853,000 | – | 174,000 | +100.0% | 0.24% | – |
| ALGN | New | ALIGN TECHNOLOGY INC | $3,453,000 | – | 23,000 | +100.0% | 0.17% | – |
| AXGT | New | AXOVANT SCIENCES LTD | $2,899,000 | – | 125,000 | +100.0% | 0.15% | – |
| GLYC | New | GLYCOMIMETICS INC | $2,511,000 | – | 225,000 | +100.0% | 0.13% | – |
| ANTH | New | ANTHERA PHARMACEUTICALS INC | $268,000 | – | 165,705 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.